SV BR 1 GM cancer vaccine - BriaCell Therapeutics
Alternative Names: Allogeneic GM CSF secreting breast cancer vaccine - BriaCell Therapeutics; Bria-IMT™; BriaVax; GM CSF gene-transfected breast cancer vaccine - BriaCell Therapeutics; SV-BR-1 breast cancer cell line vaccine - BriaCell Therapeutics; SV-BR-1-GM; SV-BR-1-GM-vaccine-BriaCell-Therapeutics; SV-BR1-GM-breast-cancer-vaccine-BriaCell-TherapeuticsLatest Information Update: 16 Dec 2024
Price :
$50 *
At a glance
- Originator Wiseman Research Initiatives LLC
- Developer BriaCell Therapeutics Corp
- Class Antineoplastics; Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- No development reported Ovarian cancer
Most Recent Events
- 11 Dec 2024 Efficacy data from phase I/II clinical trials in Breast cancer released by BriaCell
- 26 Nov 2024 Efficacy data from a phase III BRIA-ABC trial in Breast cancer released by BriaCell Therapeutics Corp
- 01 Oct 2024 Updated efficacy data from a phase I/II trial in Breast cancer released by BriaCell Therapeutics